APGE · Apogee Therapeutics, Inc.
$134.75
+0.04 (+0.03%)
At close · Aug 20
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. ... Based on the Company's current operating plan, it estimates that its existing cash and cash equivalents of $105.6 million, marketable securities of $866.4 million and long-term marketable securities of $321.9 million as of June 30, 2026, will be sufficient to enable the Company to fund its operating expenses and capital requirements through at least the next 12 months from the issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$10.20B
Shares
75.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$134.75
Open$134.72
Day$134.68–134.80
52W close$36.02–134.84
Avg vol 30d1.2M
Short int4.2M · 5.6% float · 4.0d
Short vol17%
Last earningsMay 27, 2026
DataJul 2023–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Jul 8, 2027
Est · unconfirmed
· in 46 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+52%
above
Price vs 50-day avg
+6%
above
RSI (14)
77
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+93%
trailing
YTD return
+79%
this year
Relative strength
+81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $127 › 200d $88 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +114 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.57% of float · ▲ +2.0% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
289 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
EPS growth
−28%
Y/Y
Free cash flow
$-232.6M
Balance sheet
$131.5M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
0.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+52%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
77
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $127 › 200d $88 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +114 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.57% of float · ▲ +2.0% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
289 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $36
Now $135 · 100%
Range high $135
vs 200-day avg +52%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, marketable securities and long-term marketable securities | 1.3B | Q1 2026 | — |
| Phase 1b head-to-head study enrollment | 86 | Q1 2026 | — |
| Public equity offering aggregate gross proceeds | 403M | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APGE
this stock
Apogee Therapeutics, Inc.
|
$10.20B | +78.5% | — | — | 5.6% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APGE | +0.2% | +0.4% | +92.5% | +0.5% | +78.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.2% | -3.0% | +81.3% | -1.6% | +66.7% |
Key facts
CIK
1974640
CUSIP
03770N101
13F (30d)
277 filings
275 filers
Visit website
Investor relations